SCHEMBL4265749

SCHEMBL4265749

CCCc1cc(C(=O)CCC(=O)O)ccc1OCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.54
LTB4R Q15722 1/20 0.48
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 1/20 0.46
FOS P01100 2/20 0.45
JUN P05412 2/20 0.45
TSHR P16473 1/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.43
THRA P10827 1/20 0.43
NPC1 O15118 1/20 0.42
USP2 O75604 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8217525 0.90 HSD17B10 (0.49) L3MBTL1HSD17B10ALDH1A1CYP1A2HPGD
SCHEMBL13952660 0.86 NPC1 (0.40) L3MBTL1LTB4RHSD17B10ALDH1A1FOS
SCHEMBL4264820 0.84 TSHR (0.58) L3MBTL1HSD17B10ALDH1A1CYP1A2HPGD
SCHEMBL8214127 0.81 TAS1R3 (0.55) L3MBTL1HSD17B10ALDH1A1CYP1A2HPGD
SCHEMBL4260941 0.80 MAPT (0.55) L3MBTL1HSD17B10ALDH1A1CYP1A2HPGD
SCHEMBL4257689 0.80 KMT2A (0.55) HSD17B10ALDH1A1CYP1A2HPGDCYP2C19
SCHEMBL10955996 0.80 PDE4B (0.55) L3MBTL1LTB4RHSD17B10ALDH1A1CYP1A2
SCHEMBL10919270 0.78 CYSLTR2 (0.69) CYP1A2CYSLTR2CYSLTR1
SCHEMBL4272863 0.77 ALDH1A1 (0.57) L3MBTL1HSD17B10ALDH1A1CYP1A2HPGD
SCHEMBL9120028 0.76 CTNNB1 (0.49) L3MBTL1HSD17B10ALDH1A1CYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048258-A1 Amide Compound TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-19 US disclosed
US-20090048258-A1 Amide Compound TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-19 US disclosed
EP-1845081-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048258-A1 Amide Compound DLAT, DGAT1, DGAT2 L3MBTL1 2152/4885LTB4R 3889/4885HSD17B10 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.